This inventor holds 2 USPTO granted patents. Top assignee: Astrazeneca Ab. Active years: 2006-2007.
Company Filing History:
Years Active: 2006-2007
Title: Eric Grazzini: Innovator in Pharmaceutical Assays
Introduction
Eric Grazzini is a notable inventor based in St. Laurent, Canada. He has made significant contributions to the field of pharmaceutical assays, holding a total of 2 patents. His work focuses on developing methods to screen for compounds that interact with specific receptors, which is crucial for advancing therapeutic options.
Latest Patents
Eric's latest patents include innovative assays designed to screen for compounds that bind to the dorsal root receptor. The first patent is directed towards assays that can identify compounds acting as agonists, antagonists, or inverse agonists of bovine adrenal medulla docosapeptide (BAM-22P). These assays leverage the binding properties of BAM-22P to both rat and human DRR receptors. The second patent involves a method for assaying agonists or antagonists of Dynorphin A binding to the MAS receptor. This invention aims to screen for compounds that interact with Dynorphin A and its analogues, utilizing the binding characteristics to rat and human MAS receptors.
Career Highlights
Eric Grazzini is currently employed at AstraZeneca AB, where he continues to contribute to the field of pharmaceutical research. His expertise in assay development has positioned him as a valuable asset within the company.
Collaborations
Throughout his career, Eric has collaborated with notable colleagues, including Sultan Ahmad and Paolo Lembo. These partnerships have enhanced his research and contributed to the success of his inventions.
Conclusion
Eric Grazzini's work in developing assays for pharmaceutical applications demonstrates his commitment to innovation in the field. His contributions are paving the way for new therapeutic discoveries and advancements.